Affinity Asset Advisors’s Viking Therapeutics VKTX Stock Holding History

Affinity Asset Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-332,600	Closed	-$3.68M	–	99
2023 Q3	$3.68M	Sell	332,600 -17,400	-5%	-$249K	1.04%	33
2023 Q2	$5.67M	Buy	350,000 +256,100	+273%	+$5.37M	1.98%	16
2023 Q1	$1.56M	Buy	+93,900	New	+$970K	0.52%	46

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Affinity Asset Advisors's VKTX Position: Q2 2025 in Review

Affinity Asset Advisors sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 25,000 shares — an estimated $604K sold.

Affinity Asset Advisors first reported a position in VKTX in Q3 2022 and held it in 8 quarters. The position peaked at $10.4M in Q1 2023. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

Affinity Asset Advisors reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
Affinity Asset Advisors sold 25,000 Viking Therapeutics shares in Q2 2025, an estimated $604K.
Affinity Asset Advisors first reported a position in Viking Therapeutics in Q3 2022 and held it in 8 quarters.
Affinity Asset Advisors's Viking Therapeutics position peaked at $10.4M in Q1 2023.
391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Affinity Asset Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.